These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 32507642)

  • 41. Thrombin activatable fibrinolysis inhibitor (TAFI) in cord blood.
    Uszyński W; Uszyński M; Zekanowska E; Góralczyk K
    Folia Histochem Cytobiol; 2007; 45(1):33-6. PubMed ID: 17378243
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Activated TAFI Promotes the Development of Chronic Thromboembolic Pulmonary Hypertension: A Possible Novel Therapeutic Target.
    Satoh T; Satoh K; Yaoita N; Kikuchi N; Omura J; Kurosawa R; Numano K; Al-Mamun E; Siddique MA; Sunamura S; Nogi M; Suzuki K; Miyata S; Morser J; Shimokawa H
    Circ Res; 2017 Apr; 120(8):1246-1262. PubMed ID: 28289017
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of protein S in the activation of thrombin activatable fibrinolysis inhibitor (TAFI) and regulation of fibrinolysis.
    Mosnier LO; Meijers JC; Bouma BN
    Thromb Haemost; 2001 Oct; 86(4):1040-6. PubMed ID: 11686322
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A new functional assay of thrombin activatable fibrinolysis inhibitor.
    Guimarães AH; Bertina RM; Rijken DC
    J Thromb Haemost; 2005 Jun; 3(6):1284-92. PubMed ID: 15946219
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Assessment of plasminogen activator inhibitor-1(PAI1) and thrombin activitable fibrinolysis inhibitor (TAFI) in Egyptian children with hemophilia A.
    Soliman M; Osman N; Hefnawy S; El Hawy MA
    Pediatr Hematol Oncol; 2022 May; 39(4):318-328. PubMed ID: 34668834
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative evaluation of stable TAFIa variants: importance of alpha-helix 9 and beta-sheet 11 for TAFIa (in)stability.
    Ceresa E; De Maeyer M; Jonckheer A; Peeters M; Engelborghs Y; Declerck PJ; Gils A
    J Thromb Haemost; 2007 Oct; 5(10):2105-12. PubMed ID: 17666015
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A.
    Antovic J; Schulman S; Eelde A; Blombäck M
    Haemophilia; 2001 Nov; 7(6):557-60. PubMed ID: 11851753
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis.
    Lisman T; Leebeek FW; Mosnier LO; Bouma BN; Meijers JC; Janssen HL; Nieuwenhuis HK; De Groot PG
    Gastroenterology; 2001 Jul; 121(1):131-9. PubMed ID: 11438502
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
    Colucci M; D'Aprile AM; Italia A; Gresele P; Morser J; Semeraro N
    Thromb Haemost; 2001 Apr; 85(4):661-6. PubMed ID: 11341502
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Thrombin activatable fibrinolysis inhibitor: a putative target to enhance fibrinolysis.
    Vercauteren E; Gils A; Declerck PJ
    Semin Thromb Hemost; 2013 Jun; 39(4):365-72. PubMed ID: 23457049
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasma carboxypeptidase U (CPU, CPB2, TAFIa) generation during in vitro clot lysis and its interplay between coagulation and fibrinolysis.
    Leenaerts D; Aernouts J; Van Der Veken P; Sim Y; Lambeir AM; Hendriks D
    Thromb Haemost; 2017 Jul; 117(8):1498-1508. PubMed ID: 28692110
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Profibrinolytic effects of rivaroxaban are mediated by thrombin-activatable fibrinolysis inhibitor and are attenuated by a naturally occurring stabilizing mutation in enzyme.
    Garabon JJW; Boffa MB
    J Thromb Thrombolysis; 2023 Aug; 56(2):283-290. PubMed ID: 37310666
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Activated thrombin-activatable fibrinolysis inhibitor attenuates the angiogenic potential of endothelial cells: potential relevance to the breast tumour microenvironment.
    Bazzi ZA; Balun J; Cavallo-Medved D; Porter LA; Boffa MB
    Clin Exp Metastasis; 2017 Feb; 34(2):155-169. PubMed ID: 28124276
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New insights into factors affecting clot stability: A role for thrombin activatable fibrinolysis inhibitor (TAFI; plasma procarboxypeptidase B, plasma procarboxypeptidase U, procarboxypeptidase R).
    Bouma BN; Meijers JC
    Semin Hematol; 2004 Jan; 41(1 Suppl 1):13-9. PubMed ID: 14872415
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Stimulation of thrombin- and plasmin-mediated activation of thrombin-activatable fibrinolysis inhibitor by anionic molecules.
    Plug T; Meijers JC
    Thromb Res; 2016 Oct; 146():7-14. PubMed ID: 27564657
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?
    Antovic JP; Schulman S; An SS; Greenfield RS; Blombäck M
    Scand J Clin Lab Invest; 2004; 64(8):745-51. PubMed ID: 15719893
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Generation of a stable activated thrombin activable fibrinolysis inhibitor variant.
    Ceresa E; Van de Borne K; Peeters M; Lijnen HR; Declerck PJ; Gils A
    J Biol Chem; 2006 Jun; 281(23):15878-83. PubMed ID: 16595693
    [TBL] [Abstract][Full Text] [Related]  

  • 58. PI3-Kinase Inhibitor LY294002 Repressed the Expression of Thrombin-Activatable Fibrinolysis Inhibitor in Human Hepatoma HepG2 Cells.
    Masuda Y; Yazawa J; Makino Y; Takada K
    Biol Pharm Bull; 2015; 38(10):1529-35. PubMed ID: 26424017
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles.
    Boffa MB; Koschinsky ML
    Clin Biochem; 2007 Apr; 40(7):431-42. PubMed ID: 17331488
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Thrombomodulin suppresses invasiveness of HT1080 tumor cells by reducing plasminogen activation on the cell surface through activation of thrombin-activatable fibrinolysis inhibitor.
    Higuchi T; Nakamura T; Kakutani H; Ishii H
    Biol Pharm Bull; 2009 Feb; 32(2):179-85. PubMed ID: 19182372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.